Top menu

Custom Search 1


English Caption: 

Exciting new cancer research, using data collected from the Australian Synchrotron, could lead to a new approach to the treatment of Acute Myeloid Leukaemia (AML). AML is an aggressive form of cancer affecting the blood and bone marrow, and has poor survival rates. Patients can be treated with chemotherapy to induce remission, but there is a high likelihood of relapse.

Published in major international journal Cell Reports, the research defines precisely how a newly developed therapeutic antibody, CSL362, binds to AML cancer cells. Once bound the antibody is able to recruit the body’s own immune system to kill the cancer cells, potentially preventing relapse of the disease.

This image shows Acute Myeloid Leukemia. Image courtesy of SA Pathology.

More information about this research is available in the press release "New Therapy Targets Aggressive Form of Leukaemia."